Overview

Relapse Prevention for Bipolar Type-II Disorder

Status:
Completed

Trial end date:
2007-01-01

Target enrollment:

Participant gender:

Summary

This 62-week study will compare the safety and effectiveness of fluoxetine (Prozac®), lithium, the combination of these two medications, and placebo in treating and preventing recurrent depressive episodes in people with bipolar type II disorder.

Phase:

Phase 4

Details

Lead Sponsor:

University of Pennsylvania

Collaborator:

National Institute of Mental Health (NIMH)

Treatments:

Fluoxetine